89Zirconium-labelled girentuximab (89Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma.

person Dickon Hayne UWA Medical School, University of Western Australia, Perth, Australia info_outline Dickon Hayne, Richard Gauci, Mohammed Al-Zubaidi, Pravin Viswambaram, Steve P McCombie, Elizabeth Chien Hern Liow, Nat Lenzo, Thomas Ferguson, Paola Antonini, Danielle Meyrick, Colin Hayward, Andrew David Redfern

Authors person Dickon Hayne UWA Medical School, University of Western Australia, Perth, Australia info_outline Dickon Hayne, Richard Gauci, Mohammed Al-Zubaidi, Pravin Viswambaram, Steve P McCombie, Elizabeth Chien Hern Liow, Nat Lenzo, Thomas Ferguson, Paola Antonini, Danielle Meyrick, Colin Hayward, Andrew David Redfern Organizations UWA Medical School, University of Western Australia, Perth, Australia, Fiona Stanley Hospital, Perth, Australia, Fiona Stanley Hospital, Murdoch, Australia, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Camperdown, NSW, Australia, GENESISCARE, East Fremantle, Australia, Telix Pharmaceuticals, North Melbourne, Australia, Premier Research, Durham, NC Abstract Disclosures Research Funding Pharmaceutical/Biotech Company South Metropolitan Health Service WA Background: Bladder cancer is a lethal disease with a rising incidence. The current standard imaging modalities for staging are either CT of the chest, abdomen and pelvis or FDG PET/CT. However, there are issues with using these modalities for staging. CT is known to have relatively low sensitivity for detecting low volume metastatic disease, while FDG is predominantly renally excreted and therefore has intense activity in the urinary tract, which limits its utility to detect bladder or upper tract lesions, or nodal metastases in close proximity to the urinary tract. Zirconium-89-Girentuximab (89Zr-TLX250) may have utility in the accurate staging of bladder and urothelial cancer, with less renal excretion as compared to FDG, however this has not previously been investigated. ZipUp is an investigator initiated trial. South Metropolitan Health Service WA is the trial sponsor. The study received funding and study drug support from Telix Pharmaceuticals Methods: ZiPUP is a single-arm, phase I trial examining the feasibility, safety, and utility of 89Zr-TLX250 PET/CT in patients either undergoing pre-operative staging of urothelial carcinoma or bladder cancer for curative intent, or with known metastatic urothelial carcinoma or bladder cancer. All participants will undergo 89Zr-TLX250 PET/CT and will need to have undergone recent FDG PET/CT for means of comparison. This trial aims to recruit 10 participants undergoing staging and 10 participants with known metastatic disease. The primary endpoint is effectiveness by assessing sensitivity and specificity in detecting lymph node metastases compared to FDG PET/CT; secondary endpoints are safety, tolerability, and feasibility. The first patient was enrolled in this single site study and the study is expected to be completed by December 2022. If 89Zr-TLX250 PET/CT is proven to be feasible, safe, and effective in staging urothelial cancer, it could improve the appropriate selection of treatment for patients with metastatic or primary urothelial carcinoma or bladder cancer. Clinical trial information: NCT05046665.